Trial Profile

Catalina-2: A Phase 2 Study Evaluating the Efficacy and Safety of TORL-1-23 in Women With Advanced Platinum-Resistant Epithelial Ovarian Cancer (Including Primary Peritoneal and Fallopian Tube Cancers) Expressing Claudin 6

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 03 Jul 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs TORL-1-23 (Primary)
Indications Fallopian tube cancer; Lung cancer; Ovarian cancer; Peritoneal cancer; Solid tumours
Focus Registrational; Therapeutic Use
Acronyms Catalina-2
Sponsors TORL Biotherapeutics

02 Dec 2024 Status changed from not yet recruiting to recruiting.
15 Nov 2024 Status changed from planning to not yet recruiting.
10 Apr 2024 According to a TORL BioTherapeutics media release, company announced $158M Series B-2 Financing led by Deep Track Capital.Proceeds from this Series B-2 financing will be used to continue the clinical development of this trial.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com